with the dose of isoprenaline which increased heart rate by 25 beats min-'. 4 The dose/response curves of both isoprenaline/HR and metoprolol/HR were significantly shifted to the right in IDDM-patients with hypoglycaemia unawareness compared with controls and IDDM-patients with hypoglycaemia awareness (P < 0.05). 5 Reduced sensitivity of isoprenaline stimulation has also been shown before, whereas reduced sensitivity of a blocking agent has not earlier been shown. 6 These findings support the hypothesis of reduced ,-adrenergic sensitivity as one pathophysiological component in hypoglycaemia unawareness.
Introduction
Studies of hypoglycaemia unawareness report frequencies of the condition varying from 8 to 70%. In a review of 15 studies by Gerich et al. [1] the weighted average prevalence of hypoglycaemia unawareness in populations of diabetic patients was estimated to be 25%. The term hypoglycaemia unawareness refers to a condition with absence of autonomic warning symptoms or lack of ability to recognize them, before neuroglycopenia develops. The autonomic warning symptoms, such as sweating, tremor, palpitations, ,-adrenergic sensitivity hunger and anxiety, are usually the first to be elicited when the blood glucose level decreases. They are aroused by increased release of adrenaline, noradrenaline and acetylcholine, and most often they appear at a blood glucose level of about 3.4 mM. When blood glucose concentration falls below 2.8 mM, neurologic symptoms appear [2, 3] . No single pathophysiological mechanism can explain the condition of hypoglycaemia unawareness. The aim of this study has been to investigate the changes in peripheral tissue sensi-tivity to P-adrenergic agents as one possible mechanism which may contribute to hypoglycaemia unawareness. Other authors have shown that IDDMpatients with hypoglycaemia unawareness have a reduced sensitivity of ,B-adrenoceptor stimulators [4, 5] . In this study we have also performed sensitivity tests of the j,B-adrenergic receptor blocker metoprolol.
Methods

Subjects
The study was performed on three groups of age and sex matched test persons: 1) The control group which comprised nine healthy volunteers, five females and four males, mean age 29.1 years (age range 23-40 years). 2) Seven IDDM-patients with hypoglycaemia awareness, four males and three females, mean age 30.1 years (age range 23-42 years). 3) Nine IDDMpatients with hypoglycaemia unawareness, three females and six males, mean age 31.4 years (age range 21-41). The patients were selected among IDDM-patients asked by a questionnaire about the frequency and severity of their hypoglycaemic episodes, their symptoms and need of assistance during hypoglycaemia. The duration of disease was significantly longer (P < 0.01) in the unaware-group (mean 18 years, range 7-30 years) than in the awaregroup (mean 5 years, range y-12 years). All patients were on multiinjection insulin treatment. The test persons gave a written informed consent to take part in the study. The study was approved by the Ethics Committee of the Norwegian Health Region V.
Protocol
The isoprenaline/metoprolol sensitivity test was carried out in a quiet room between 09.00 and 13.00 h. It has been found that the period of day in which the isoprenaline sensitivity test is performed does not influence the result of the test [6] . There was no extraordinary dietary restrictions or intervention in insulin therapy.
The isoprenaline sensitivity test was performed when the test person had rested in bed for 30 min. Bolus injections of isoprenaline (isoprenaline 0.2 mg ml-', Hydro Pharma, Oslo, Norway) were given intravenously in a forearm vein through a three-way valve. Blood samples were obtained from arterialized venous blood in the other forearm through another three-way valve. Both the intravenous catheter for injections and the intravenous catheter for blood sampling were continuously perfused at a low rate with 0.9% NaCl during the test. The injection valve and intravenous catheter were flushed with 5 ml 0.9% NaCl after each injection. From each blood sample the first 5 ml were discarded.
The starting isoprenaline dose was 0.25 ,ug according to George et al [6] . This was doubled until heart rate had increased at least 30 beats min-1 above the basal level. The maximum isoprenaline dose given was 8 jg. The next isoprenaline injection was given 2-3 min after the heart rate had returned to its basal level. This procedure gave an injection interval of 5-10 min.
The metoprolol sensitivity test was performed after the isoprenaline sensitivity test. Together with the dose of isoprenaline which increased heart rate with 25 beats min-1 (TEST 125), increasing doses of metoprolol (Seloken® 1 mg ml-', Hassle, M6lndal, Sweden) were injected. Starting dose of metoprolol was 0.5 mg and this was doubled until heart rate no longer increased above the basal level. Maximum metoprolol dose was 8 mg. The isoprenaline dose was kept constant during the metoprolol sensitivity test. Methods of injections and blood sampling were identical with the isoprenaline sensitivity test.
Heart rate was registered with an instantaneous rate meter (Propaq® 104EL, Protocol® systems, INC., Beaverton, Oregon 97006 USA). The same apparatus was used on all test persons. Blood pressures were measured (Propaq® 104EL) and blood samples were obtained before start of the test and on peak isoprenaline effect after each isoprenaline or isoprenaline/metoprolol injection (50-70 s after injection).
Catecholamine and isoprenaline concentrations
The following chemicals were employed: (±)-Adrenaline bitartrate, noradrenaline bitartrate, (±)-isoprenaline hydrochloride and (±)-dihydroxybenzylamine hydrobromide from Sigma Chemical Corp., St. Louis, MO, USA. All other chemicals were of analytical grade. Blood with heparin (4 iu ml-1), reduced glutathione (4.5 nM) and EGTA (5 mM) was kept on ice before centrifugation at 1.000 g for 20 min at 40 C. The samples were stored at -20°C awaiting analysis. Standards and samples were prepared as described previously [7] . Plasma concentrations of catecholamines and isoprenaline were measured by h.p.l.c.
The high performance liquid chromatography setup of catecholamines and isoprenaline analysis included: 590 Solvent delivery module, U6K injector, 460 electrochemical detector and M740 data module (Millipore Corp., Waters Chromatography Division, Milford, MA, USA). A Clin-Rep® column and eluent (Pharma Vertriebs GmbH & Co KG, Munich, FRG) were employed for the chromatography performed at ambient temperature. Eluent flow was 1.0 ml min-1.
Metoprolol concentrations
The following chemicals were employed: Metoprolol and H93/47 (AB Hassle, M6lndal, Sweden), dichloromethane and diethyl ether (E. Meck, Darmstadt, FRG), triethylamine and acetonitrile of HPLCgrade (Rathburn Chemicals, Walkerburn, UK. Blood with heparin (4 iu ml-') was kept on ice before centrifugation at 1.000 g for 20 min at 40 C. The samples were stored at -20°C awaiting analysis on h.p.l.c.
H.p.l.c. setup of metoprolol analysis: The samples and standards were essentially prepared according to [8] with following modifications: H93/47 (50 ,l of 10 gl ml-') was used as internal standard, tri- Table 2a , ordinate intercept in Table 2b . (Table 3 ). The slopes of the glucose dose-response curves of both IDDM-groups were significantly different from the slope of the dose-response curve of the controls (Table 2a) . We observed a fall in the blood level of glucose in both IDDM-groups, whereas a rising glucose level was observed in the controls. All changes of blood levels of glucose were significantly correlated to the dose of isoprenaline given. The pharmacodynamic effects of metoprolol have been measured by the same variables as in the isoprenaline sensitivity test. Heart rate and systolic blood pressure showed a significant negative correlation to the dose of metoprolol. There were no significant changes in diastolic blood pressure, blood levels of glucose, plasma levels of adrenaline or noradrenaline (results not shown).
Reduced effect of metoprolol on heart rate was demonstrated in IDDM-patients with hypoglycaemia unawareness by right-shifted dose-response curves (Figure 2) , compared with controls. There were no significant differences in metoprolol response . ,
I
I between controls and IDDM-patients with hypoglycaemia awareness. M_12.5 can be used as a standard of metoprolol sensitivity. In Table 3 it is shown that M-l2.s was significantly increased in IDDM-patients with hypoglycaemia unawareness.
Plasma levels of isoprenaline and metoprolol
The plasma levels of isoprenaline were measured in blood samples obtained after each injection of 8 ,ug.
In both IDDM-groups the plasma levels of isoprenaline were significantly higher than in controls (IDDM-aware: 3.01 nm, s.d. [19] [20] [21] . On the other hand intensified insulin therapy is also reported to weaken the catecholamine response to hypoglycaemia [22] . Patients treated with intensified insulin therapy with the intention to achieve near-normal blood glucose levels, go through severe hypoglycaemic episodes more often than patients on traditional insulin therapy [23] . It is shown that hypoglycaemia unawareness in IDDM patients on intensified insulin therapy, may be reversed by increasing their HBAic and careful prevention of hypoglycaemic episodes [24] . Further investigation of the effect of insulin therapy on adrenergic sensitivity must be important. The isoprenaline and metoprolol sensitivity tests have shown to be useful tools in this work.
